Tarceva
(erlotinib)ApprovedSmall molecule
Erlotinib is used to treat certain types of lung cancer and pancreatic cancer by blocking proteins that help cancer cells grow and survive.[2] Tarceva is currently approved and in use across 39 indications[4].[1]
Tarceva is one of 539 small molecule programs targeting Pancreatic Neoplasm. It is currently in Approved.
39
Indications
622
Total Trials
1
Active Trials
538
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 39 indications
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tarceva
OOSI Pharmaceuticals
Approved
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Serplulimab
Shanghai Henlius BiotechPhase 3
Zimberelimab
Arcus BiosciencesPhase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Treatment
GSKPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer58 trials
Show 55 more trials
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT00499655·107 enrolled
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT00660816·46 enrolled
Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
Terminated·—·Phase 2·NCT01857271·3 enrolled
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT00950365·79 enrolled
Pancreatic Cancer17 trials
Show 14 more trials
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00313560·48 enrolled
Breast Cancer10 trials
Show 7 more trials
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
Completed·—·Phase 2·NCT00054275·39 enrolled
Glioblastoma Multiforme9 trials
Show 6 more trials
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00086879·110 enrolled
Squamous Cell Carcinoma6 trials
Show 3 more trials
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Completed·—·Phase 2·NCT00720304·43 enrolled
66 more indications
Metastatic Colorectal Cancer4 trials
Show 1 more trial
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
Completed·—·Phase 1·NCT00118261·17 enrolled
Lung Cancer4 trials
Show 1 more trial
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Completed·—·N/A·NCT00125372·12 enrolled
Liver Cancer4 trials
Malignant Glioma4 trials
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Completed·—·Phase 2·NCT00672243·32 enrolled
Patients With Advanced Solid Tumors3 trials
Recurrent Head and Neck Cancer3 trials
Brain Metastases3 trials
Colorectal Cancer3 trials
Glioma2 trials
Lung Adenocarcinoma2 trials
Small Cell Lung Cancer2 trials
Prostate Cancer2 trials
Esophageal Cancer2 trials
Head and Neck Cancer2 trials
Bevacizumab2 trials
Kidney Cancer2 trials
Fallopian Tube Cancer2 trials
Intestinal Cancer2 trials
Bladder Cancer2 trials
Metastatic Head and Neck Cancer2 trials
Biliary Tract Cancer2 trials
Safety and Efficacy1 trial
Locally-advanced Rectal Cancer1 trial
Cervical Cancer1 trial
Recurrent or Refractory Solid Tumors1 trial
Unresectable1 trial
Urothelial Cancer1 trial
Mesothelioma1 trial
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Completed·—·Phase 2·NCT00137826·37 enrolled
Solid Tumor Malignancies1 trial
Metastatic Solid Tumors1 trial
Elderly Patients1 trial
Recurrent Cancer1 trial
Renal Cell Carcinoma1 trial
Gastroesophageal Junction1 trial
Unresectable Solid Tumor1 trial
Head and Neck Squamous Cell Cancer1 trial
Renal Cell Cancer1 trial
Growth1 trial
Squamous Cell Cancer of the Head and Neck1 trial
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Terminated·—·Phase 2·NCT01192815·2 enrolled
Cancer1 trial
Endometrial Cancer1 trial
Malignant Peripheral Nerve Sheath Tumor1 trial
Radiation Therapy1 trial
Advanced NSCLC1 trial
High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
Unknown status·—·Phase 2·NCT01965275·20 enrolled
Primary Peritoneal Cancer1 trial
EGFR Activating Mutation1 trial
Second-line Treatment1 trial
MPA1 trial
Recurrent1 trial
Ph I Dasatinib + Erlotinib in Recurrent MG
Completed·—·Phase 1·NCT00609999·47 enrolled
First-line Treatment1 trial
Malignant Peritoneal Mesothelioma1 trial
Gallbladder Cancer1 trial
Acute Myeloid Leukemia1 trial
Intensity-modulated Radiation Therapy1 trial
Regulatory
FDA Approval Timeline[5]
Nov 18, 2004
TARCEVA
NDA NDA021743
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tarceva drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for erlotinib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Epidermal Growth Factor Receptor Erbb1 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- OOSI Pharmaceuticals